Shire PLC SHP StarRatingValueLabel_2

Latest Morningstar Commentary
DateAuthor Headline
14/02/2013Alanna Petroff FTSE Falls from 5-Year High
THURSDAY MARKET UPDATE: Shire and AMEC contribute to a 0.5% decline on the FTSE 100, ending a four-day market rally
29/11/2011Holly Cook Shire Shares Overvalued After Rally
Morningstar Equity Research implies the market is overvaluing the pharma stock relative to its fair value
09/11/2011Karen Andersen, CFA Raising Our Fair Value Estimate for Shire
Shire's 3Q was in line with our expectations but we're boosting our fair value estimate on ADHD potential and Sanofi's extended Fabrazyme shortages
17/10/2011Holly Cook These Stocks Are Currently Under- and Overvalued
Despite market weakness, Morningstar Stock Research highlights several stocks that remain overvalued, plus a few that offer upside potential

Latest Company News

DateTimeSourceHeadlineType
Previous Stories...
21/05/201307:00PRNSHIRE PLC - Transaction in Own SharesPOS
20/05/201312:00DJPRESS RELEASE: Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform For Development Of ZFP Therapeutics(R) For Monogenic DiseasesNEW
18/05/201303:27DJDJ Holder RUSSELL Registers 32,661 Of SHIRE PLC >SHPGTRS
17/05/201315:05DJPRESS RELEASE: Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual MeetingNEW
16/05/201307:00PRNSHIRE PLC - Transaction in Own SharesPOS
14/05/201303:20DJDJ Holder RUSSELL Registers 45,936 Of SHIRE PLC >SHPGTRS
13/05/201311:03DJDJ ANALYST RATINGS CHANGES AS OF 0700 GMTCOM
13/05/201309:15DJDJ ANALYST RATINGS CHANGES AS OF 0700 GMTCOM
13/05/201308:05DJDJ ANALYST RATINGS CHANGES AS OF 0700 GMTOUT
09/05/201317:21DJPRESS RELEASE: Shire Wins Patent Trial Against Watson Concerning LIALDA(R)NEW
09/05/201317:05DJDJ Shire Prevails in Litigation over LIALDA Colitis TreatmentOUT
09/05/201316:58PRNSHIRE PLC - Shire Wins Patent Trial Against Watson concerning LIALDASTC
09/05/201307:00PRNSHIRE PLC - Transaction in Own SharesPOS
08/05/201315:00PRNSHIRE PLC - Purchase of Shares by Employee Benefit TrustPOS
08/05/201307:00PRNSHIRE PLC - Transaction in Own SharesPOS
07/05/201307:00PRNSHIRE PLC - Transaction in Own SharesPOS
03/05/201314:45PRNSHIRE PLC - Director’s Share DealingsRDS
03/05/201307:00PRNSHIRE PLC - Transaction in Own SharesPOS
02/05/201312:25DJPRESS RELEASE: New Chief Executive Reports Q1 Results and Sets out Strategy for GrowthERN
02/05/201312:00DJPRESS RELEASE: New Chief Executive Reports Q1 Results and Sets out Strategy for GrowthERN
Regulatory News Abstract
DateType Story
21/05/2013StoryTypeOSB Purchase of own securities
61,912 Ords at 2,066p to 2,090p (Treasury)
16/05/2013StoryTypeOSB Purchase of own securities
45,690 Ords at 2,039p to 2,063p (Treasury)
09/05/2013StoryTypeOSB Purchase of own securities
0.16m Ords at 1,866p to 1,919p (Treasury)
09/05/2013Business Event Wins patent trial against Watson
The company announces that its subsidiary, Shire Development LLC, has prevailed in its litigation against Watson Pharmaceuticals Inc., Watson Laboratories, Inc.-Florida, Watson Pharma, Inc. and Watson Laboratories, Inc. in connection with their Abbreviated New Drug Application (ANDA) for a generic version of the company's LIALDA® delayed release tablets for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis
08/05/2013StoryTypeOSB Purchase of own securities
0.26m Ords at 1,855p to 1,874p (Treasury)
07/05/2013StoryTypeOSB Purchase of own securities
0.22m Ords at 1,855p to 1,884p (Treasury)
03/05/2013StoryTypeOSB Purchase of own securities
0.57m Ords at 1,868p to 2,021p (Treasury)
02/05/2013Trading Statement Expects to deliver earnings growth
"...we continue to expect to deliver earnings growth in line with current consensus earnings expectations for 2013"
02/05/2013StoryTypeOSB Purchase of own securities
39,915 Ords at 2,009p to 2,038p (Treasury)
30/04/2013StoryTypeOSB Purchase of own securities
42,240 Ords at 1,998p to 2,016p (Treasury)
30/04/2013Business Event Result of AGM
At the company's AGM held on 30 April 2013, all resolutions including special resolutions to dis-apply pre-emption rights, to authorise market purchases of company's shares and to call a General Meeting other than an AGM on not less than 14 clear days' notice, will be proposed
26/04/2013StoryTypeOSB Purchase of own securities
0.15m Ords at 1,982p to 2,003p (Treasury)
26/04/2013StoryTypeOSB Purchase of own securities
0.15m Ords at 1,982p to 2,003p (Treasury)
25/04/2013StoryTypeOSB Purchase of own securities
41,254 Ords at 2,003p to 2,022p (Treasury)
25/04/2013Business Event Settles INTUNIV Litigation
The company announces that its subsidiary, Shire LLC, has settled all pending litigation with Actavis, Inc., Actavis LLC, and Actavis Elizabeth LLC and Watson Laboratories, Inc.-Florida, Watson Pharma, Inc. and ANDA, Inc. in connection with Actavis' and Watson's Abbreviated New Drug Applications for generic versions of the company's INTUNIV® for the treatment of Attention Deficit Hyperactivity Disorder. The settlement provides Actavis with a license to make and market Actavis' generic versions of INTUNIV in the United States on 1 December 2014, or earlier in certain limited circumstances
24/04/2013StoryTypeOSB Purchase of own securities
54,500 Ords at 1,988p to 2,011p (Treasury)
23/04/2013StoryTypeOSB Purchase of own securities
0.18m Ords at 1,978p to 2,003p (Treasury)
19/04/2013StoryTypeOSB Purchase of own securities
0.15m Ords at 1,933p to 1,968p (Treasury)
18/04/2013StoryTypeOSB Purchase of own securities
88,200 Ords at 1,918p to 1,952p (Treasury)
16/04/2013StoryTypeOSB Purchase of own securities
0.12m Ords at 1,961p to 1,995p (Treasury)
12/04/2013StoryTypeOSB Purchase of own securities
0.12m Ords at 1,941p to 1,970p (Treasury)
11/04/2013StoryTypeOSB Purchase of own securities
91,900 Ords at 1,930p to 1,953p (Treasury)
10/04/2013StoryTypeOSB Purchase of own securities
71,900 Ords at 1,941p to 1,958p (Treasury)
09/04/2013StoryTypeOSB Purchase of own securities
61,500 Ords at 1,935p to 1,946p (Treasury)
05/04/2013StoryTypeOSB Purchase of own securities
88,500 Ords at 1,966p to 1,982p (Treasury)
03/04/2013StoryTypeOSB Purchase of own securities
0.11m Ords at 1,980p to 2,007p (Treasury)
28/03/2013StoryTypeOSB Purchase of own securities
88,000 Ords at 1,968p to 1,989p (Treasury)
28/03/2013Trading Statement Enjoy the next chapter of growth
ch - "Looking ahead, we are well prepared to enjoy the next chapter of growth in our ongoing story.
27/03/2013StoryTypeOSB Purchase of own securities
58,700 Ords at 1,973p to 3,003p (Treasury)
26/03/2013StoryTypeOSB Purchase of own securities
97,500 Ords at 1,975p to 2,001p (Treasury)
25/03/2013Acquisition Acquisition of SARcode Bioscience
The company announces that it will acquire SARcode Bioscience Inc. Under the terms of agreement, the company will make an upfront payment of $160m and SARcode shareholders will be eligible to receive additional undisclosed payments upon achievement of certain clinical, regulatory, and/or commercial milestones. The transaction is expected to close in the second quarter, subject to regulatory approval in the United States, and other customary closing conditions
25/03/2013StoryTypeOSB Purchase of own securities
0.10m Ords at 1,970p to 2,002p (Treasury)
22/03/2013StoryTypeOSB Purchase of own securities
87,100 Ords at 1,988p to 2,025p (Treasury)
20/03/2013StoryTypeOSB Purchase of own securities
38,000 Ords at 2,013p to 2,032p (Treasury)
19/03/2013StoryTypeOSB Purchase of own securities
31,563 Ords at 2,008p to 2,038p (Treasury)
15/03/2013StoryTypeOSB Purchase of own securities
39,455 Ords at 2,050p to 2,070p (Treasury)
13/03/2013StoryTypeOSB Purchase of own securities
33,700 Ords at 2,029p to 2,058p (Treasury)
12/03/2013StoryTypeOSB Purchase of own securities
37,000 Ords at 2,035p to 2,051p (Treasury)
07/03/2013StoryTypeOSB Purchase of own securities
57,600 Ords at 2,087p to 2,092p (Treasury)
06/03/2013StoryTypeOSB Purchase of own securities
35,500 Ords at 2,093p to 2,102p (Treasury)
01/03/2013StoryTypeOSB Purchase of own securities
95,750 Ords at 2,057p to 2,084p (Treasury)
28/02/2013StoryTypeOSB Purchase of own securities
36,300 Ords at 2,094p to 2,110p (Treasury)
26/02/2013StoryTypeOSB Purchase of own securities
28,551 Ords at 2,116p to 2,142p (Treasury)
22/02/2013StoryTypeOSB Purchase of own securities
50,953 Ords at 2,047p to 2,083p (Treasury)
20/02/2013StoryTypeOSB Purchase of own securities
47,900 Ords at 2,050p to 2,069p (Treasury)
18/02/2013StoryTypeOSB Purchase of own securities
82,442 Ords at 2,021p to 2,080p (Treasury)
15/02/2013StoryTypeOSB Purchase of own securities
0.18m Ords at 2,027p to 2,139p (Treasury)
13/02/2013StoryTypeOSB Purchase of own securities
16,500 Ords at 2,105p to 2,124p (Treasury)
11/02/2013StoryTypeOSB Purchase of own securities
21,050 Ords at 2,104p to 2,123p (Treasury)
07/02/2013StoryTypeOSB Purchase of own securities
21,800 Ords at 2,123p to 2,144p (Treasury)
05/02/2013StoryTypeOSB Purchase of own securities
33,850 Ords at 2,133p to 2,168p (Treasury)
01/02/2013Business Event Agreement in principle with US Government
The company has reached an agreement in principle to resolve the previously disclosed civil investigation into the company's U.S. sales and marketing practices relating to ADDERALL XR(R), VYVANSE(R) and DAYTRANA(R). The agreement in principle is subject to change until this matter is finally resolved. Discussions between the company and the U.S. Government are ongoing to establish a final resolution to the investigation
01/02/2013StoryTypeOSB Purchase of Own securities
16,700 Ords at 2,103p to 2,120p (Treasury)
31/01/2013StoryTypeOSB Purchase of Own securities
15,997 Ords at 2,115p to 2,120p (Treasury)
29/01/2013StoryTypeOSB Purchase of Own securities
31,062 Ords at 2,103p to 2,132p (Treasury)
25/01/2013StoryTypeOSB Purchase of own securities
62,100 Ords at 2,093p to 2,123p (Treasury)
23/01/2013StoryTypeOSB Purchase of own securities
43,341 Ords at 2,070p to 2,098p (Treasury)
21/01/2013StoryTypeOSB Purchase of own securities
58,331 Ords at 2,092p to 2,107p (Treasury)
17/01/2013StoryTypeOSB Purchase of own securities
91,500 Ords at 2,067p to 2,077p (Treasury)
16/01/2013StoryTypeOSB Purchase of own securities
34,932 Ords at 2,025p to 2,036p (Treasury)
14/01/2013StoryTypeOSB Purchase of own securities
68,000 Ords at 2,010p to 2,030p (Treasury)
10/01/2013StoryTypeOSB Purchase of own securities
0.15m Ords at 1,978p to 2,008p (Treasury)
09/01/2013StoryTypeOSB Purchase of own securities
0.20m Ords at 1,926p to 1,971p (Treasury)
07/01/2013StoryTypeOSB Purchase of own securities
0.14m Ords at 1,916p to 1,935p (Treasury)
04/01/2013StoryTypeOSB Purchase of own securities
60,221 Ords at 1,899p to 1,917p (Treasury)
03/01/2013StoryTypeOSB Purchase of own securities
78,470 Ords at 1,895p to 1,918p (Treasury)
HelpGlossaryLicensing OpportunitiesData OpportunitiesCareersContact MorningstarAdvertiseSite Map
   
Make this site my homepage
© Copyright 2012 Morningstar. All rights reserved. Terms of Use | Privacy Policy | Cookies